Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
Net cash provided by operating and investing activities was $9.1 million in the third quarter and net cash used in operating and investing activities was $84.1 million for the first nine months of 2023; quarter-end cash and restricted cash position was $673.1 millionReceived $55 million payment from Bristol Myers Sq...